Bolt Biotherapeutics shares surge 10.45% after-hours as extended cash runway into 2027 and BDC-4182 Phase 1 trial progress boost investor confidence.

Bolt Biotherapeutics surged 10.45% in after-hours trading following the release of its third-quarter 2025 financial results and business update. The company highlighted a $38.8 million cash balance expected to fund operations into 2027, a 100% year-over-year increase in collaboration revenue to $2.2 million, and progress in its BDC-4182 Phase 1 trial for gastric/gastroesophageal cancer, with initial data anticipated in Q3 2026. Management emphasized the extended cash runway and clinical advancements as catalysts for long-term shareholder value. The improved financial metrics, reduced R&D expenses, and strategic collaborations with Genmab and Toray further reinforced investor confidence in the company’s ability to advance its pipeline and achieve key milestones.